Skip to main content

06-11-2021 | ACR 2021 | Conference coverage | Video

The ARIAA trial of abatacept for subclinical arthritis

Jürgen Rech outlines the findings from the ARIAA trial, which demonstrated benefits of abatacept in people at risk for rheumatoid arthritis, and discusses the potential role of treating subclinical inflammation to delay or prevent the onset of clinical disease (7:04).

Read transcript